secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K
Filed at:   2026-02-13T23:59:59+00:00
Accession:  0001493152-26-006784
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Labs initiates sale process for BE-Smart esophageal cancer test; updates on COVID-19 receivable collections
--------------------------------------------------------------------------------

- Initiated potential sale or strategic partnership for BE-Smart, a CLIA/CAP-accredited LDT for esophageal cancer risk; outreach to >70 acquirers.
- Crown Medical Collections: >60% of aggregate claims are from commercial payors that partially reimbursed, implying higher recovery rates.
- Laboratory subsidiaries are in Chapter 11; legacy COVID-19 testing receivables being addressed via Crown Medical Collections initiative.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000149315226006784/0001493152-26-006784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000149315226006784/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-006784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer